Prostaglandin Availability and Association with Outcomes for XXXX with @entity299 .

@entity1 @entity75 @entity1699 @entity5014 @entity5015 @entity880 @entity299 @entity1011 @entity413
UNASSIGNED: Data regarding availability of @entity5015 ( @entity5014 ) and its impact on the stabilization, transport, critical care course, and surgical outcome of @entity1 with ductal-dependent @entity299 in the current pediatric healthcare environment are unknown. We sought to determine the proportion of hospitals in Texas that stock @entity5014 and to investigate associations between @entity5014 availability and clinical outcomes. All birth institutions listed with the Texas Department of Health and @entity1 Services were contacted to determine @entity5014 availability as of 2011. Outcomes of all @entity1 admitted to our institution from 2007 to 2012 who received @entity5014 for @entity75 were evaluated. @entity5014 was stocked in 50  % (n  =  139) of hospitals that performed deliveries in Texas in 2011 representing 79.1  % (303, 481) of births. Hospitals that did not stock @entity5014 had less annual births and were located a further distance from a center that provided pediatric cardiac surgical services. @entity1 born at a hospital that did not stock @entity5014 had significantly greater serum @entity880 and @entity1011 (p  =  0.002) and serum @entity880 on admission (p  <  0.001). The @entity5014 availability was not associated with hospital length of stay, postoperative length of stay, or mortality. When stratifying in TGA and @entity1699 subgroups, lack of @entity5014 availability remained associated with higher @entity1011 , higher @entity880 , lower @entity413 , and lower pH. @entity5014 is not universally available in all healthcare institutions providing obstetrical services. Lack of availability of @entity5014 at an outlying hospital was associated with increased morbidity, but was not associated with mortality or length of stay.
